Overview

* Rapt Therapeutics ( RAPT ) Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024

* Company completed $250 mln public offering to strengthen balance sheet

* R&D expenses decreased due to lower costs in several areas

Outlook

* RAPT plans to report Phase 2 asthma trial results next year

* Company to discuss CSU registrational pathway with FDA

* RAPT's cash projected to fund operations to mid-2028

Result Drivers

* PUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.65

Q3 Net -$17.58

Income mln

Q3 Basic -$0.65

EPS

Q3 $19.37

Operatin mln

g

Expenses

Q3 -$19.37

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for RAPT Therapeutics Inc ( RAPT ) is $60.00, about 52.9% above its November 5 closing price of $28.27

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)